Immobilized OX40 Ligand/TNFSF4 His Tag, Cynomolgus (Cat. No. UA010778) at 2.0μg/mL (100μL/well) can bind OX40/TNFRSF4/CD134Fc Chimera, Cynomolgus (Cat. No. UA010869) with EC50 of 29.4-43.16ng/mL.
Product Details
Product Details
Product Specification
Species | Cynomolgus |
Synonyms | Txgp1; OX40L receptor; ACT35 |
Accession | XP_001090870.1 |
Amino Acid Sequence | Lys28-Ala214, with C-terminal hIgG1 Fc |
Expression System | HEK293 |
Molecular Weight | 65-72kDa (Reducing) |
Purity | >95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, pH7.4. |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Reference | Cancer Res. Roles of OX40 in the pathogenesis and the control of diseases.Int J Hematol . 2006 Jan;83(1):17-22. |
Background
OX40 belongs to the tumor necrosis factor receptor superfamily, and its expression is restricted to activated T-cells. Ligation of OX40 during T-cell-dendritic cell interaction is crucial for clonal expansion of antigen-specific T-cells and generation of T-cell memory. Recent studies with animal models have indicated the critical involvement of OX40 in the pathogenesis of a variety of immunologic abnormalities of inflammatory, autoimmune, infectious, allergic, and allotransplantation-related diseases. Blockade of OX40-OX40L(The ligand of OX40) interaction has been shown to prevent, cure, or ameliorate these diseases. In contrast, activation of OX40 is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. These findings clearly suggest that the OX40/OX40L system is one of the most promising targets of immune intervention for treatment of these diseases.
Picture
Picture
Bioactivity

SDS-PAGE
1μg (R: reducing condition, N: non-reducing condition).
